Register 3 for the price of 2 with the coupon code rcdvb!
registration button

September 12-13, 2016

10th Neurodegenerative Conditions Research & Development

September 14-15, 2016

9th CNS Partnering & Deal-Making

GTCbio offers comprehensive sponsorship packages for all our meetings, including presentation opportunities, exhibit and booth space, as well as the event delegate list. All our packages can be customized to meet your company's budget. For information, please contact:

Amber Kempf
626-256-6405 x110
amber.kempf [at]

GTCbio encourages attendees to showcase their research at the conference by presenting a poster. The top 2-3 submitted posters will also be selected to give short oral presentations as part of the meeting program. Abstracts will be accepted until August 12, 2016; slots fill up quickly so submit yours online ASAP!

Speakers | Agenda | Venue | Sponsors | Poster Submissions

Dear Colleague,

We are excited to announce the CNS Diseases World Summit, to be held on September 12-15, 2016 in Boston, MA. This meeting provides an interactive learning and relationship-building forum for all players in the CNS field. Colleagues from industry, academia, government agencies, and financing bodies will gather at the interface of research, partnerships, funding, and commercialization to find ways to move forward in a field that has been troubled with clinical failures.

The program will provide a comprehensive look at the current state of CNS, from research to commercialization. Above all, this event will provide networking opportunities in an intimate and accessible environment.

The CNS Diseases World Summit consists of two, back-to-back conferences:

10th Neurodegenerative Conditions Research & Development
Sessions include:
I. Novel Therapeutics & Approaches in Alzheimer’s Disease
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Rare and Orphan CNS Disorders
IV. Neuroinflammation Across CNS Disorders
V. Biomarkers: Translation from Discovery to Clinical
VI. Advances in Genetics and Systems Biology

9th CNS Partnering & Deal-Making
Sessions include:
I. Panel Discussion: What Sells Big Pharma in CNS
II. Panel Discussion: An Update on Neurodegeneration and the State of the Art
III. Session: Partnering with Patient Groups to Advance Research
IV. Panel Discussion: Regulatory Considerations for Orphan Drug Products
V. Session: CNS: Present and Future
VI. Panel Discussion: CNS Perspectives: Venture Capital and Public Markets
VII. Session: Partnering & Licensing in CNS.

A summit pass will get you access to both conferences. We invite you to join us as we connect, build relationships, and seek new ways forward into the future of CNS research and development. br />
We hope to see you there!

Best regards,

The 2016 Advisory Committee

2016 Advisory Board Members
Mark Allegretta, National Multiple Sclerosis Society
Gai Ayalon, Genetech
Robert Bell, Pfizer
Luca Benatti, EryDel
Adam Bristol, Aquilo Capital Management
Karen Chandross, Sanofi
Monica Coenraad, Rett Syndrome Research Trust
Frank Eeckman, Mavericks Capital
Lisa Ellerby, The Buck Institute
Howard Fillit, Alzheimer’s Drug Discovery Foundation
Daniel Grau, Sojournix
Marlene Haffner, Haffner Associates
Andreas Jeromin, NextGen Sciences Dx
Jeff Karan, Mavericks Capital
Robyn Klein, Washington University School of Medicine
David Michelson, Merck & Co.
John Renger, Merck & Co.
Susanna Rosi, University of California, San Francisco
Bavani Shankar, AstraZeneca
Jared Sterneckert, Technische Universität Dresden
Srinivasa Subramaniam, Scripps Research Institute
Gabriel Vargas, Amgen


Attend all GTCbio Conferences for one year for only $4,995 ($2,495 for academic and government).
Click here to sign up!

cns-diseases-world-summit Overview